naa a22 4500 510763219 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s12094-012-0953-5 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0953-5 Prevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey [Elektronische Daten] [J. Steegmann, J. Sánchez Torres, R. Colomer, Á. Vaz, J. López, I. Jalón, M. Provencio, A. González-Martín, M. Pérez] Background: The present study aimed to provide updated data on anaemia prevalence and management in cancer patients undergoing systemic therapy in Spain. Methods: This was a multicenter, observational, cross-sectional study performed in 2008. Eligible patients were ≥18years, with non-myeloid malignancies treated with systemic therapy [chemotherapy (CT), hormonal therapy or immunotherapy]. Anaemia was defined according to WHO as haemoglobin (Hb) <12g/dL. Results: The study included 214 patients with a median age of 63years (range 20-91), 58% women, 73% with solid tumours, and 79% with advanced disease. CT was used in 91% of patients (26% with platinum compounds), hormonal therapy in 8.5%, and immunotherapy in 8.5%. In our study, 48.1% of patients [95% confidence interval (CI) 45.2-58.6] showed anaemia (31% symptomatic): 42.0% mild (10≤Hb≤11.9g/dL), 5.6% moderate (8≤Hb≤9.9g/dL), and 0.5% severe (Hb<8g/dL). A higher prevalence was observed in patients treated with CT (51 vs. 20%, p=0.01), platinum-based CT (70 vs. 47%, p=0.01) or palliative CT (61 vs. 39%, p=0.003). Anaemia was also more frequent in patients with more than three lines of CT (83%) and in the fourth or subsequent CT cycle (58%). Management in the previous 4weeks in patients with anaemia was: 62% did not receive treatment (92% mild), 24% received erythropoiesis-stimulating agents (ESAs), 14% received iron and 8.7% received transfusion. Conclusions: In Spanish hospitals, about half of patients with non-myeloid malignancies undergoing systemic therapy fulfilled anaemia criteria (87% mild). Approximately two-third of patients with anaemia do not receive specific treatment and ESA use is below current guidelines. The Author(s), 2012 Anaemia nationallicence Darbepoetin alfa nationallicence Chemotherapy nationallicence Solid tumours nationallicence Haematological malignancies nationallicence Transfusion nationallicence Steegmann J. Servicio de Hematología, Hematology Department, Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, Diego de Leon, 62, 28006, Madrid, Spain aut Sánchez Torres J. Servicio de Oncología Médica, Hospital 12 de Octubre, Madrid, Spain aut Colomer R. Servicio Oncología Médica, M.D. Anderson Cancer Center, Madrid, Spain aut Vaz Á. Departamento de Hematología, Hospital Ramón y Cajal, Madrid, Spain aut López J. Departamento de Hematología, Hospital Ramón y Cajal, Madrid, Spain aut Jalón I. Departamento de Hematología, Clínica Ruber, Madrid, Spain aut Provencio M. Departamento de Oncología Médica, Hospital Puerta de Hierro, Madrid, Spain aut González-Martín A. Servicio Oncología Médica, M.D. Anderson Cancer Center, Madrid, Spain aut Pérez M. Servicio de Oncología, Hospital Universitario de la Princesa, Madrid, Spain aut Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 477-483 1699-048X 15:6<477 2013 15 12094 https://doi.org/10.1007/s12094-012-0953-5 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0953-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Steegmann J. Servicio de Hematología, Hematology Department, Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, Diego de Leon, 62, 28006, Madrid, Spain aut NATIONALLICENCE 700 1- Sánchez Torres J. Servicio de Oncología Médica, Hospital 12 de Octubre, Madrid, Spain aut NATIONALLICENCE 700 1- Colomer R. Servicio Oncología Médica, M.D. Anderson Cancer Center, Madrid, Spain aut NATIONALLICENCE 700 1- Vaz Á. Departamento de Hematología, Hospital Ramón y Cajal, Madrid, Spain aut NATIONALLICENCE 700 1- López J. Departamento de Hematología, Hospital Ramón y Cajal, Madrid, Spain aut NATIONALLICENCE 700 1- Jalón I. Departamento de Hematología, Clínica Ruber, Madrid, Spain aut NATIONALLICENCE 700 1- Provencio M. Departamento de Oncología Médica, Hospital Puerta de Hierro, Madrid, Spain aut NATIONALLICENCE 700 1- González-Martín A. Servicio Oncología Médica, M.D. Anderson Cancer Center, Madrid, Spain aut NATIONALLICENCE 700 1- Pérez M. Servicio de Oncología, Hospital Universitario de la Princesa, Madrid, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 477-483 1699-048X 15:6<477 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer